A marketing authorization application for lecanemab, an investigational anti-amyloid beta (A) protofibril antibody, has been submitted by BioArctic AB’s (publ) partner Eisai to the Pharmaceuticals and Medical Devices Agency for the treatment of mild cognitive impairment (MCI) brought on by Alzheimer’s disease (AD) and mild Alzheimer’s dementia (collectively known as […]
Featured News
Autolomous aims to provide digital solutions to Centers for Breakthrough Medicines to streamline and automate cell and gene therapy manufacturing
The US Center for Breakthrough Medicines (CBM), a Cell and Gene Therapy Contract Organization for Development, Manufacturing, and Testing, has entered into a licencing agreement with Autolomous LTD, the market-leading developer of critical manufacturing management systems for cell and gene therapies (CGT) (CDMO). With the help of the agreement, Autolomous […]
Introduction of Diagnostic and Supplemental Imaging Legislation Could Benefit Thousands of New Mexicans
Representative Christine Chandler (D-Los Alamos), who has partnered with Susan G. Komen to introduce legislation that would eliminate financial restrictions on imaging that can rule out breast cancer or confirm the need for a biopsy, is commended by Komen. Komen is the world’s largest breast cancer organisation. In New Mexico, […]
Berkeley Lights Launches Beacon Select™, A New Optofluidic System For Cell Line Development
The life sciences toolmaker Berkeley Lights, Inc. announced the release of Beacon SelectTM, a new optofluidic system for cell line development (CLD). The Beacon Select expands upon the cutting-edge technology provided by the original Beacon system, which was introduced in 2017 and has more than 130 systems already placed throughout […]
Ipsen to Acquire Albireo Accelerating Growth in Rare Disease With Treatments for Several Pediatric Liver Diseases
Ipsen and Albireo declared today that they have signed a binding merger agreement under which Ipsen would buy Albireo, a pioneer in the development of bile-acid modulators for the treatment of cholestatic liver disorders in both children and adults. The upcoming acquisition will improve Ipsen’s pipeline and portfolio for rare […]
Fusion Pharmaceuticals and BWXT Medical Announce Actinium-225 Partnership to Scale Supply for Developing Targeted Alpha Therapies
It was disclosed that BWXT Medical Ltd., a division of BWX Technologies, Inc., and Fusion Pharmaceuticals Inc. had signed a preferred partner agreement for the delivery of actinium-225. According to the contract, BWXT Medical will supply Fusion with defined volumes of actinium at volume-based prices. An alpha-emitting isotope called actinium-225 […]
Deciphera Pharmaceuticals Announces Planned 2023 Corporate Milestones to Support Continued Evolution to Multi-Product Company
In addition to announcing preliminary unaudited fourth quarter and full year 2022 revenue, Deciphera Pharmaceuticals, Inc., a biopharmaceutical company dedicated to discovering, developing, and commercialising significant new medicines to improve the lives of people with cancer, today highlighted its strategic outlook for 2023 and planned 2023 corporate milestones. Deciphera revealed […]
Community Health System and Health Net Agree on Multi-year Network Contract
In order to better serve the inhabitants of Fresno county, Health Net and Community Health System have announced they will maintain their long-standing cooperation. Existing and prospective Health Net members registered in commercial, Medicare, and Medi-Cal plans will still have access to the full range of services provided by Community. […]
Novavax Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates
The COVID-19-Influenza Combination (CIC) and influenza stand-alone vaccine candidates will now be tested in a Phase 2 trial, according to Novavax, Inc., a biotechnology company committed to creating and marketing next-generation vaccines for critical infectious diseases. The CIC and influenza vaccine candidates will be evaluated for safety and efficacy (immunogenicity) […]
ZIRCON Phase III Renal Cancer Study to be Presented at ASCO GU along with Theranostic Pipeline Advances
Telix Pharmaceuticals Limited reports that an oral presentation of the recently finished pivotal Phase III ZIRCON study of TLX250-CDx (Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) will take place at the upcoming 2023 ASCO GU Symposium, which will take place in San Francisco, California, from February 16–18, 2023. The […]
